Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Global pharmaceutical company
EP Vantage Medtech 2016 in Review
The annual EP Vantage Medtech 2016 in Review report offers analysis and expert commentary on M&A deals venture financing, initial public offerings and FDA approvals in the medtech sector during 2016.
2016 was a year of enormous change on the political stage. For the medical device industry, though, it was fairly quiet, with the pyrotechnics of 2015 a fast-fading memory.
Key findings include:
- The total value of M&A deals fell to $42bn, far below 2015’s total of $128bn
- Medtech companies raised a total of $3.7bn in 2016, down slightly from the year before, but the number of rounds continues to decline steeply
- At 38 in 2016, premarket approvals and humanitarian device exemptions saw a 25% decline from 2015; but de novo clearances were up, with 24 last year compared with 18 in 2015
EP Vantage is an independent editorial team providing daily commentary and analysis that allows our readers to quickly understand what is important and why. Our high quality, data-driven analysis is trusted, insightful and thought provoking, enabling our readers to make informed decisions.
EP Vantage Pharma & Biotech 2016 in Review
Confirm your details on form below to download this report